(AGENPARL) – NEW HAVEN, CONNECTICUT (USA) lun 05 giugno 2023 A new Yale-led study finds improved survival rates and reduced risk of recurrence of non-small cell lung cancer with the drug osimertinib following surgery.
Fonte/Source: https://www.yalecancercenter.org/news-article/yale-cancer-center-led-study-shows-osimertinib-improves-survival-following-surgery-for-non-small-cell-lung-cancer/